Spark Therapeutics Reports 2016 Financial Results and Business Highlights
February 22, 2017 07:30 ET
|
Spark Therapeutics, Inc.
Investigational voretigene neparvovec Biologics License Application (BLA) on track for completion in early 2017 Three additional clinical-stage programs continue to advance, including initiation of...
Spark Therapeutics to Host Conference Call on Wednesday, Feb. 22 at 8:30 a.m. to Discuss 2016 Results
February 15, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
Spark Therapeutics to Participate in Multiple February Conferences
January 26, 2017 07:36 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy
January 09, 2017 07:30 ET
|
Spark Therapeutics, Inc.
FDA grants request to amend orphan drug designation for voretigene neparvovec to encompass all Inherited Retinal Disease (IRD) caused by biallelic RPE65 mutations, which is aligned with proposed...
Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program
January 04, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
January 03, 2017 16:05 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics Adds Chief Operating Officer to Management Team
December 05, 2016 07:01 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences
December 05, 2016 07:00 ET
|
Spark Therapeutics, Inc.
Exclusive use of Selecta’s Synthetic Vaccine Particles (SVP™) platform technology provided to Spark Therapeutics for co-administration with up to five gene therapy targets, including FVIII for...
Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
December 03, 2016 11:00 ET
|
Spark Therapeutics, Inc.; Pfizer Inc.
Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days Seven infused participants who have progressed to at least 12 weeks...
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia B Phase 1/2 Data at American Society of Hematology Annual Meeting
November 30, 2016 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...